179 related articles for article (PubMed ID: 21504204)
21. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid.
Chen L; Zhang Y; Kong X; Lan E; Huang Z; Peng S; Kaufman DL; Tian J
J Med Chem; 2008 Aug; 51(15):4834-8. PubMed ID: 18598019
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effect of geranylamine derivatives on human hepatoma.
Akiyama K; Kumamoto T; Wada S; Miura H; Nomura M; Yokogawa K; Miyamoto K
In Vivo; 2005; 19(1):173-8. PubMed ID: 15796170
[TBL] [Abstract][Full Text] [Related]
23. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.
Zhao J; Zhang X; Shi M; Xu H; Jin J; Ni H; Yang S; Dai J; Wu M; Guo Y
Hepatology; 2006 Jul; 44(1):205-15. PubMed ID: 16799960
[TBL] [Abstract][Full Text] [Related]
24. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
25. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
Mor A; Kloog Y; Keren G; George J
Eur J Pharmacol; 2009 Aug; 616(1-3):301-5. PubMed ID: 19527709
[TBL] [Abstract][Full Text] [Related]
26. Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.
Buonsanti MF; Bertinaria M; Stilo AD; Cena C; Fruttero R; Gasco A
J Med Chem; 2007 Oct; 50(20):5003-11. PubMed ID: 17845020
[TBL] [Abstract][Full Text] [Related]
27. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
Ma Y; Wang J; Liu L; Zhu H; Chen X; Pan S; Sun X; Jiang H
Cancer Lett; 2011 Feb; 301(1):75-84. PubMed ID: 21078540
[TBL] [Abstract][Full Text] [Related]
28. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
[TBL] [Abstract][Full Text] [Related]
29. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
30. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
Okano J; Nagahara T; Matsumoto K; Murawaki Y
Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):543-51. PubMed ID: 18346049
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and anti-hepatocellular carcinoma activity of novel O
Zou Y; Yan C; Liu JC; Huang ZJ; Xu JY; Zhou JP; Zhang HB; Zhang YH
Chin J Nat Med; 2017 Dec; 15(12):928-937. PubMed ID: 29329650
[TBL] [Abstract][Full Text] [Related]
32. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
33. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
34. Second generation of alpha-tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization.
López GV; Blanco F; Hernández P; Ferreira A; Piro OE; Batthyány C; González M; Rubbo H; Cerecetto H
Bioorg Med Chem; 2007 Sep; 15(18):6262-72. PubMed ID: 17627828
[TBL] [Abstract][Full Text] [Related]
35. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
36. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
37. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study.
Ghous Z; Akhter J; Pourgholami MH; Morris DL
Anticancer Res; 2008; 28(6A):3757-61. PubMed ID: 19189661
[TBL] [Abstract][Full Text] [Related]
39. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
40. Novel antileukemic agents derived from tamibarotene and nitric oxide donors.
Bian H; Feng J; Li M; Xu W
Bioorg Med Chem Lett; 2011 Dec; 21(23):7025-9. PubMed ID: 22014829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
